Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone626-305-5900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$40.60 million
Profitability
Miscellaneous
Employees156
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
Xencor (NASDAQ:XNCR) Frequently Asked Questions
What is Xencor's stock symbol?
Xencor trades on the NASDAQ under the ticker symbol "XNCR."
How were Xencor's earnings last quarter?
Xencor Inc (NASDAQ:XNCR) posted its earnings results on Tuesday, August, 6th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.45) by $0.15. The biopharmaceutical company had revenue of $19.49 million for the quarter, compared to analysts' expectations of $7.58 million. Xencor had a net margin of 28.46% and a return on equity of 8.40%. View Xencor's Earnings History.
When is Xencor's next earnings date?
What price target have analysts set for XNCR?
10 Wall Street analysts have issued twelve-month price targets for Xencor's stock. Their predictions range from $21.00 to $67.00. On average, they anticipate Xencor's stock price to reach $45.29 in the next year. This suggests a possible upside of 29.1% from the stock's current price. View Analyst Price Targets for Xencor.
What is the consensus analysts' recommendation for Xencor?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last year. There are currently 1 sell rating, 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xencor.
What are Wall Street analysts saying about Xencor stock?
Here are some recent quotes from research analysts about Xencor stock:
- 1. According to Zacks Investment Research, "Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. " (10/5/2019)
- 2. Nomura analysts commented, "‘18087 (SSTR2xCD3) 2H19 to 1H20, 0 Est ASCO as Expected. SSTR2 is a validated target in NET and GIST, but these are solid tumors and suffer from tumor microenvironment effects and potential on-target toxicities. ‘18087 (SSTR2xCD3) is now the only bispecific in XNCR’s platform that we currently value. NVS to Our View. Recall, the clinical hold lifted in April; dosing to resume in coming weeks, but “tunable potency” still in question. Last update on clinicaltrials.gov was May 2 and included a Aug 2019 study completion date – we anticipate with appropriate study completion, NVS will return rights. More p 3. Checks – XNCRs’s Bispec C max -Dependent with Redesign." (8/8/2019)
- 3. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and 12-month price target of $40. Xencor reported 1Q 2019 earnings and offered a Business Update. No Ultromaris royalties were booked because they are booked ~1-2 quarters in arrears vs. Alexion. The company did have $112M in revenue from February’s Genentech deal, resulting in positive EPS for the quarter. Ultromaris and MOR208 revenues remain fast-approaching, near-term revenue opportunities. Alexion (ALXN: NC) reported $25M in Ultromaris sales in 1Q 2019. Xencor receives a low-single-digit royalty on these revenues; we model a 2% royalty." (5/12/2019)
Has Xencor been receiving favorable news coverage?
Media headlines about XNCR stock have been trending somewhat negative recently, InfoTrie reports. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Xencor earned a media sentiment score of -1.5 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Xencor.
Are investors shorting Xencor?
Xencor saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 4,460,000 shares, an increase of 10.7% from the August 30th total of 4,030,000 shares. Based on an average daily trading volume, of 592,100 shares, the days-to-cover ratio is presently 7.5 days. Approximately 8.0% of the company's stock are sold short. View Xencor's Current Options Chain.
Who are some of Xencor's key competitors?
Some companies that are related to Xencor include Ionis Pharmaceuticals (IONS), Bausch Health Companies (BHC), SAGE Therapeutics (SAGE), Perrigo (PRGO), Catalent (CTLT), Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT), Beigene (BGNE), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Horizon Therapeutics (HZNP), Reata Pharmaceuticals (RETA), The Medicines (MDCO) and Ascendis Pharma A/S (ASND).
What other stocks do shareholders of Xencor own?
Who are Xencor's key executives?
Xencor's management team includes the folowing people:
- Dr. Bassil I. Dahiyat Ph.D., Co-Founder, CEO, Pres & Director (Age 49)
- Mr. John J. Kuch, Sr. VP of Fin., CFO & Sec. (Age 60)
- Dr. John R. Desjarlais, Sr. VP of Research & Chief Scientific Officer (Age 55)
- Dr. Paul A. Foster, Sr. VP & Chief Medical Officer (Age 65)
- Mr. Charles Liles, Associate Director and Head of Corp. Communications & Investor Relations
Who are Xencor's major shareholders?
Xencor's stock is owned by many different of retail and institutional investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.53%), State of Alaska Department of Revenue (0.07%), CIBC Private Wealth Group LLC (0.04%), Crossmark Global Holdings Inc. (0.02%) and Everence Capital Management Inc. (0.02%). Company insiders that own Xencor stock include Bassil I Dahiyat, Edgardo Baracchini Jr, Edgardo Baracchini, Jr, John J Kuch, John R Desjarlais, John S Stafford III and Paul A Foster. View Institutional Ownership Trends for Xencor.
Which major investors are selling Xencor stock?
XNCR stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB and CIBC Private Wealth Group LLC. Company insiders that have sold Xencor company stock in the last year include John J Kuch and John R Desjarlais. View Insider Buying and Selling for Xencor.
Which major investors are buying Xencor stock?
XNCR stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Crossmark Global Holdings Inc. and Everence Capital Management Inc.. View Insider Buying and Selling for Xencor.
How do I buy shares of Xencor?
Shares of XNCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Xencor's stock price today?
One share of XNCR stock can currently be purchased for approximately $35.08.
How big of a company is Xencor?
Xencor has a market capitalization of $1.99 billion and generates $40.60 million in revenue each year. The biopharmaceutical company earns $-70,410,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis. Xencor employs 156 workers across the globe.View Additional Information About Xencor.
What is Xencor's official website?
How can I contact Xencor?
Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The biopharmaceutical company can be reached via phone at 626-305-5900 or via email at [email protected]
MarketBeat Community Rating for Xencor (NASDAQ XNCR)
MarketBeat's community ratings are surveys of what our community members think about Xencor and other stocks. Vote "Outperform" if you believe XNCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XNCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
